Nuclear Localization of IRG1 Modulates COX2 Expression and Prostaglandin Biosynthesis in Primary Human Macrophages 2308479

A Anthony Cannon (Eli Lilly and Co) K Katie Acken R Robert Benschop (Eli Lilly and Company) L Luke Bourner (Eli Lilly and Company) L Linda Chung (Eli Lilly and Company) C Chuck Dorsey (Watershed Pharma) A Andrew Grigdesby (Eli Lilly and Company) I Ian Lamb (Eli Lilly and Company) A Anne Mc-GettrickDillon (Trinity College) L Luke O’Neill (Trinity College) A Abigail Pajulas (Eli Lilly and Company) J Jaiya Randhawa (Trinity College) C Chunlao Tang (Eli Lilly and Company) C Cindy Wang (Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville) J Junpeng Xiao J Jordan Yokubonus (Eli Lilly and Company)

Abstract

Abstract Introduction Immunometabolism within macrophages represents a dynamic process modulated by environmental factors and pathological conditions. Immune Responsive Gene 1 (IRG1) catalyzes the conversion of cis-aconitate, an intermediate in the tricarboxylic acid (TCA) cycle, to itaconate, and is robustly upregulated in macrophages following toll-like receptor engagement or type II interferon stimulation. The upregulation of IRG1 results in reduced macrophage cytokine production and influences polarization. To date, IRG1 localization has primarily been associated with mitochondria. In this study, we present evidence that IRG1 is also present in the nucleus of macrophages, where it associates with several promoters, including one controlling expression of PTGS2 (COX2), the rate-limiting enzyme in prostaglandin synthesis. Methods In these studies, we employed a multi-omic strategy incorporating ChIP-seq, RNA-seq, global proteomics, and metabolomics. To establish the biological significance of this novel IRG1 function, we generated CRISPR knockouts in human monocyte-derived macrophages and utilized a DSS-induced colitis model to assess inflammation in vivo. Results Through a multi-omic approach encompassing ChIP-seq, RNA-seq, global differential proteomics, and metabolomics, we have elucidated a nuclear function for IRG1 in primary human macrophages influencing prostaglandin biosynthesis. Additionally, investigations using a CRISPR-generated catalytically inactive IRG1 point mutant in THP1 cells demonstrated significant binding of IRG1 to the PTGS2 promoter, resulting in increased COX2 transcript and protein expression independent of itaconate production. Conclusion Collectively, these results reveal a novel, nuclear role for IRG1 in macrophages that provides a deeper understanding of how IRG1 may regulate macrophage function in the context of inflammation. Funding Source Eli Lilly and Company Topic Categories Cellular Adhesion, Migration, and Inflammation (CAM)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (16)

A

Anthony Cannon

Eli Lilly and Co

K

Katie Acken

R

Robert Benschop

Eli Lilly and Company

L

Luke Bourner

Eli Lilly and Company

L

Linda Chung

Eli Lilly and Company

C

Chuck Dorsey

Watershed Pharma

A

Andrew Grigdesby

Eli Lilly and Company

I

Ian Lamb

Eli Lilly and Company

A

Anne Mc-GettrickDillon

Trinity College

L

Luke O’Neill

Trinity College

A

Abigail Pajulas

Eli Lilly and Company

J

Jaiya Randhawa

Trinity College

C

Chunlao Tang

Eli Lilly and Company

C

Cindy Wang

Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville

J

Junpeng Xiao

J

Jordan Yokubonus

Eli Lilly and Company